短腸症候群の世界市場レポート 2025年

短腸症候群市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は14.6%で、53億3,000万米ドルに成長します。予測期間に予測される成長は、短腸症候群（SBS）の有病率の上昇、非経口・経腸栄養療法の採用拡大、臨床研究・医薬品開発の拡大、ヘルスケア支出の増加、SBSの認知度向上と早期診断など、いくつかの要因に起因しています。予測期間における主な動向としては、腸管リハビリテーション療法の発展、小腸移植技術の開発、SBS管理における遠隔医療の採用、経腸栄養デバイスの技術革新、SBS治療計画における人工知能の統合などが挙げられます。

消化器疾患の有病率の増加は、今後数年間の短腸症候群市場の成長を促進すると予想されます。消化管疾患には、胃、腸、肝臓、膵臓などの消化管に影響を及ぼすさまざまな疾患が含まれ、消化や栄養吸収が損なわれることが多いです。これらの疾患の増加は、腸の健康を乱し、炎症を促進する不健康な食習慣が主な原因となっています。胃腸障害は、損傷した腸管部分の外科的切除を必要とし、腸の栄養吸収能力を低下させることにより、短腸症候群に寄与する可能性があります。例えば、2023年9月、炎症性腸疾患（IBD）臨床研究センターは、カナダでは32万人以上が炎症性腸疾患（IBD）に罹患しており、有病率は毎年2.44％増加すると予測していると報告しました。2035年までには、推定47万人のカナダ人がIBDと共存することになります。その結果、消化器疾患の有病率の増加が短腸症候群市場の成長を後押ししています。

短腸症候群市場の主なプレーヤーは、消化器疾患患者の予後を改善するために、腸管不全の最先端治療法の開発に注力しています。腸管不全は、小腸が十分な栄養素、水分、電解質を吸収できず、水分補給や栄養補給が損なわれる深刻な状態です。例えば、2024年5月、米国のヘルスケア企業であるアイアンウッド・ファーマシューティカルズ社は、次世代GLP-2アナログであるアプラグルチドについて、短腸症候群で腸管障害を有する成人を対象とした試験から得られた新たなデータを発表しました。apraglutideは、腸管吸収を促進し、非経口的サポートへの依存を軽減する可能性を示し、この薬剤の安全性、有効性、長期的ベネフィットを強調しました。この進歩は、消化器疾患に対する革新的な治療法の開発に対するアイアンウッドの献身を強調するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界短腸症候群 PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の短腸症候群市場：成長率分析
• 世界の短腸症候群市場の実績：規模と成長, 2019-2024
• 世界の短腸症候群市場の予測：規模と成長, 2024-2029, 2034F
• 世界短腸症候群総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の短腸症候群市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• グルカゴン様ペプチド（GLP-2）
• 成長ホルモン
• グルタミン
• 世界の短腸症候群市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 身体検査
• 血液検査
• 便脂肪検査
• 画像検査手順
• その他の診断
• 世界の短腸症候群市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 栄養療法
• 医薬品
• 手術
• 移植
• 世界の短腸症候群市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 専門薬局
• その他の流通チャネル
• 世界の短腸症候群市場、（グルカゴン様ペプチド）GLP-2のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• テドグルチド
• その他のGLP-2類似体
• 世界の短腸症候群市場成長ホルモンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ソマトロピン
• その他の成長ホルモン療法
• 世界の短腸症候群市場グルタミンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口グルタミン
• 静脈内グルタミン

第7章 地域別・国別分析

• 世界の短腸症候群市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の短腸症候群市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 短腸症候群市場：競合情勢
• 短腸症候群市場：企業プロファイル
  • Nestle SA Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • Nutrinia Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Zealand Pharma
• Baxter International Inc.
• Alnylam Pharmaceuticals
• OPKO Health Inc
• Ironwood Pharmaceuticals Inc.
• Hanmi Pharm Co. Ltd
• Ardelyx Inc
• Emmaus Life Sciences Inc
• Jaguar Health
• 31.13. OxThera Inc.
• 31.14. Adocia SAS
• 31.15. EnteraBio Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 短腸症候群市場2029：新たな機会を提供する国
• 短腸症候群市場2029：新たな機会を提供するセグメント
• 短腸症候群市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Short bowel syndrome (SBS) is a malabsorption disorder that occurs due to the loss or dysfunction of a significant portion of the small intestine, leading to impaired nutrient and fluid absorption. This often results in symptoms such as diarrhea, dehydration, electrolyte imbalances, and malnutrition. The severity of these symptoms depends on the length of the remaining intestine and its ability to adapt. SBS can have a major impact on overall health, requiring careful dietary and medical management.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of treatments in short bowel syndrome include glucagon-like peptide (GLP-2), growth hormone, and glutamine. GLP-2, an intestinal hormone, plays a vital role in enhancing nutrient absorption, promoting intestinal growth, and reducing inflammation in the gut, making it a key focus for therapeutic approaches in conditions such as SBS. Diagnosis involves physical exams, blood tests, fecal fat tests, imaging procedures, and other assessments. Treatment options include nutritional therapy, medications, surgery, and transplants, which are provided through various channels such as hospital pharmacies, specialty pharmacies, and others.

The short bowel syndrome market research report is one of a series of new reports from The Business Research Company that provides short bowel syndrome market statistics, including short bowel syndrome industry global market size, regional shares, competitors with a short bowel syndrome market share, detailed short bowel syndrome market segments, market trends and opportunities, and any further data you may need to thrive in the short bowel syndrome industry. This short bowel syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The short bowel syndrome market size has grown rapidly in recent years. It will grow from$2.69 billion in 2024 to $3.09 billion in 2025 at a compound annual growth rate (CAGR) of 14.9%. The growth observed in the historic period can be attributed to several factors, including the increasing prevalence of gastrointestinal disorders, rising healthcare spending and expanded insurance coverage, advancements in post-surgical management of SBS, a higher incidence of Crohn's disease and other gastrointestinal disorders, and improvements in parenteral nutrition formulations and administration techniques.

The short bowel syndrome market size is expected to see rapid growth in the next few years. It will grow to$5.33 billion in 2029 at a compound annual growth rate (CAGR) of 14.6%. The growth projected for the forecast period can be attributed to several factors, including the rising prevalence of short bowel syndrome (SBS), increasing adoption of parenteral and enteral nutrition therapies, expanding clinical research and drug development, higher healthcare expenditure, and greater awareness and early diagnosis of SBS. Key trends in the forecast period include advancements in intestinal rehabilitation therapies, the development of small intestine transplantation techniques, the adoption of telemedicine for SBS management, technological innovations in enteral feeding devices, and the integration of artificial intelligence in SBS treatment planning.

The increasing prevalence of gastrointestinal diseases is expected to drive the growth of the short bowel syndrome market in the coming years. Gastrointestinal diseases encompass a wide range of conditions affecting the digestive tract, including the stomach, intestines, liver, and pancreas, often impairing digestion and nutrient absorption. The rise in these diseases is largely driven by unhealthy dietary habits that disrupt gut health and promote inflammation. Gastrointestinal disorders can contribute to short bowel syndrome by requiring surgical removal of damaged intestinal sections, which reduces the intestine's ability to absorb nutrients. For instance, in September 2023, the Inflammatory Bowel Disease (IBD) Clinical and Research Centre reported that over 320,000 people in Canada have inflammatory bowel disease (IBD), and the prevalence is expected to increase by 2.44% annually. By 2035, an estimated 470,000 Canadians will be living with IBD. Consequently, the growing prevalence of gastrointestinal diseases is boosting the growth of the short bowel syndrome market.

Key players in the short bowel syndrome market are focusing on developing cutting-edge treatments for intestinal failure to improve outcomes for patients with gastrointestinal disorders. Intestinal failure is a serious condition where the small intestine is unable to absorb sufficient nutrients, fluids, and electrolytes, compromising hydration and nutrition. For example, in May 2024, Ironwood Pharmaceuticals, Inc., a US-based healthcare company, presented new data from studies on apraglutide, a next-generation GLP-2 analog, in adults with short bowel syndrome and intestinal failure. Apraglutide showed potential to enhance intestinal absorption and reduce dependence on parenteral support, highlighting the drug's safety, efficacy, and long-term benefits. This advancement underscores Ironwood's dedication to developing innovative therapies for gastrointestinal disorders.

In May 2024, Takeda Pharmaceutical Company Limited, a Japan-based global pharmaceutical company, partnered with Inspire, a US-based patient community platform, to address the unmet needs of short bowel syndrome patients. This collaboration aims to use real-world patient insights and multidisciplinary research to identify care gaps, improve patient support, and drive innovation in treatment approaches for short bowel syndrome. Inspire connects patients with health and wellness communities to enhance patient engagement and support data-driven solutions for healthcare challenges.

Major players in the short bowel syndrome market are Nestle SA, Pfizer Inc, Johnson & Johnson, Sanofi SA, Nutrinia, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Zealand Pharma, Baxter International Inc., Alnylam Pharmaceuticals, OPKO Health Inc, Ironwood Pharmaceuticals Inc., Hanmi Pharm Co. Ltd, Ardelyx Inc, Emmaus Life Sciences Inc, Jaguar Health, 9 Meters Biopharma Inc., OxThera Inc., Adocia SAS, EnteraBio Ltd, and GLyPharma Therapeutic Inc.

North America was the largest region in the short bowel syndrome market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in short bowel syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the short bowel syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The short bowel syndrome market consists of revenues earned by entities by providing services such as medical care, diagnostic testing, nutritional support, and ongoing patient management. The market value includes the value of related goods sold by the service provider or included within the service offering. The short bowel syndrome market also includes sales of oral rehydration solutions, antidiarrheal medications, proton pump inhibitors, antimotility agents, bile acid binders, antimicrobials, and specialized enteral nutrition formulas. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Short Bowel Syndrome Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on short bowel syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for short bowel syndrome ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The short bowel syndrome market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Glucagon-Like Peptide (GLP-2); Growth Hormone; Glutamine
• 2) By Diagnosis: Physical Exam; Blood Tests; Fecal Fat Tests; Imaging Procedures; Other Diagnosis
• 3) By Treatment: Nutritional Therapy; Medications; Surgery; Transplant
• 4) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Glucagon-Like Peptide (GLP-2): Teduglutide; Other GLP-2 Analogues
• 2) By Growth Hormone: Somatropin; Other Growth Hormone Therapies
• 3) By Glutamine: Oral Glutamine; Intravenous Glutamine
• Companies Mentioned: Nestle SA; Pfizer Inc; Johnson & Johnson; Sanofi SA; Nutrinia
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Short Bowel Syndrome Market Characteristics

3. Short Bowel Syndrome Market Trends And Strategies

4. Short Bowel Syndrome Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Short Bowel Syndrome Growth Analysis And Strategic Analysis Framework

• 5.1. Global Short Bowel Syndrome PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Short Bowel Syndrome Market Growth Rate Analysis
• 5.4. Global Short Bowel Syndrome Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Short Bowel Syndrome Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Short Bowel Syndrome Total Addressable Market (TAM)

6. Short Bowel Syndrome Market Segmentation

• 6.1. Global Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Glucagon-Like Peptide (GLP-2)
• Growth Hormone
• Glutamine
• 6.2. Global Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Physical Exam
• Blood Tests
• Fecal Fat Tests
• Imaging Procedures
• Other Diagnosis
• 6.3. Global Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nutritional Therapy
• Medications
• Surgery
• Transplant
• 6.4. Global Short Bowel Syndrome Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Specialty Pharmacies
• Other Distribution Channels
• 6.5. Global Short Bowel Syndrome Market, Sub-Segmentation Of (Glucagon-Like Peptide) GLP-2, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Teduglutide
• Other GLP-2 Analogues
• 6.6. Global Short Bowel Syndrome Market, Sub-Segmentation Of Growth Hormone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Somatropin
• Other Growth Hormone Therapies
• 6.7. Global Short Bowel Syndrome Market, Sub-Segmentation Of Glutamine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Glutamine
• Intravenous Glutamine

7. Short Bowel Syndrome Market Regional And Country Analysis

• 7.1. Global Short Bowel Syndrome Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Short Bowel Syndrome Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Short Bowel Syndrome Market

• 8.1. Asia-Pacific Short Bowel Syndrome Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Short Bowel Syndrome Market

• 9.1. China Short Bowel Syndrome Market Overview
• 9.2. China Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Short Bowel Syndrome Market

• 10.1. India Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Short Bowel Syndrome Market

• 11.1. Japan Short Bowel Syndrome Market Overview
• 11.2. Japan Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Short Bowel Syndrome Market

• 12.1. Australia Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Short Bowel Syndrome Market

• 13.1. Indonesia Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Short Bowel Syndrome Market

• 14.1. South Korea Short Bowel Syndrome Market Overview
• 14.2. South Korea Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Short Bowel Syndrome Market

• 15.1. Western Europe Short Bowel Syndrome Market Overview
• 15.2. Western Europe Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Short Bowel Syndrome Market

• 16.1. UK Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Short Bowel Syndrome Market

• 17.1. Germany Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Short Bowel Syndrome Market

• 18.1. France Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Short Bowel Syndrome Market

• 19.1. Italy Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Short Bowel Syndrome Market

• 20.1. Spain Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Short Bowel Syndrome Market

• 21.1. Eastern Europe Short Bowel Syndrome Market Overview
• 21.2. Eastern Europe Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Short Bowel Syndrome Market

• 22.1. Russia Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Short Bowel Syndrome Market

• 23.1. North America Short Bowel Syndrome Market Overview
• 23.2. North America Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Short Bowel Syndrome Market

• 24.1. USA Short Bowel Syndrome Market Overview
• 24.2. USA Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Short Bowel Syndrome Market

• 25.1. Canada Short Bowel Syndrome Market Overview
• 25.2. Canada Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Short Bowel Syndrome Market

• 26.1. South America Short Bowel Syndrome Market Overview
• 26.2. South America Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Short Bowel Syndrome Market

• 27.1. Brazil Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Short Bowel Syndrome Market

• 28.1. Middle East Short Bowel Syndrome Market Overview
• 28.2. Middle East Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Short Bowel Syndrome Market

• 29.1. Africa Short Bowel Syndrome Market Overview
• 29.2. Africa Short Bowel Syndrome Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Short Bowel Syndrome Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Short Bowel Syndrome Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Short Bowel Syndrome Market Competitive Landscape And Company Profiles

• 30.1. Short Bowel Syndrome Market Competitive Landscape
• 30.2. Short Bowel Syndrome Market Company Profiles
  • 30.2.1. Nestle SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Nutrinia Overview, Products and Services, Strategy and Financial Analysis

31. Short Bowel Syndrome Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Zealand Pharma
• 31.4. Baxter International Inc.
• 31.5. Alnylam Pharmaceuticals
• 31.6. OPKO Health Inc
• 31.7. Ironwood Pharmaceuticals Inc.
• 31.8. Hanmi Pharm Co. Ltd
• 31.9. Ardelyx Inc
• 31.10. Emmaus Life Sciences Inc
• 31.11. Jaguar Health
  • 31.12. 9 Meters Biopharma Inc.
• 31.13. OxThera Inc.
• 31.14. Adocia SAS
• 31.15. EnteraBio Ltd

32. Global Short Bowel Syndrome Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Short Bowel Syndrome Market

34. Recent Developments In The Short Bowel Syndrome Market

35. Short Bowel Syndrome Market High Potential Countries, Segments and Strategies

• 35.1 Short Bowel Syndrome Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Short Bowel Syndrome Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Short Bowel Syndrome Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34967_Short_Bowel_Syndrome_GMR_2025